Moreover, we noticed that the expression of these markers remained relatively stable in MPR patients post‐treatment, but in NPR patients, there was a marked increase in HIF‐1α, GLUT1, and TGF‐β levels after treatment, indicating tumor progression and treatment resistance. The gene discussed is HIF1A; the disease is neoplasm.